Condition

Primary Sjögren's Syndrome

ClinicalTrials.gov condition label

Clinical trials6

Recruiting2

Common interventions16

Lead sponsors shown5

Clinical trials

6 shown

The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's SyndromeNCT04981145 · 2022-01-14

Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease ActivityNCT03003572 · 2018-03-27

Efficacy and Safety of S95011 in Primary Sjögren's Syndrome PatientsNCT04605978 · 2021-08-03

Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid ArthritisNCT04186871 · 2020-01-07

Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's SyndromeNCT02495129 · 2015-12-01

Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's SyndromeNCT02291029 · 2014-10-22

Common interventions

abataceptDRUG1 Blood samplesOTHER1 branebrutinibDRUG1 branebrutinib placeboDRUG1 CFZ533 active - Cohort 1DRUG1 CFZ533 active - Cohort 2DRUG1 CFZ533 active - Cohort 3DRUG1 CFZ533 active -Cohort 3DRUG1 CFZ533 placebo - Cohort 2DRUG1 CFZ533 placebo- Cohort 1DRUG1 Hydroxychloroquine Sulfate TabletsDRUG1 Iguratimod TabletsDRUG1 Placebo concentrate for solution for infusionDRUG1 S95011 concentrate for solution for infusionDRUG1 VAY736 higher doseDRUG1 VAY736 lower doseDRUG1

Leading sponsors

Novartis Pharmaceuticals2 Bristol-Myers Squibb1 Centre Hospitalier Universitaire de Saint Etienne1 Institut de Recherches Internationales Servier1 Second Affiliated Hospital, Zhejiang University, School of Medicine1

Trial status mix

COMPLETED3

RECRUITING2

WITHDRAWN1

Phase mix

PHASE24

PHASE11

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.